Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.61 |
| ▸ | PI4KA | P42356 | 2/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845625 | 1.00 | ADORA2A (0.76) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| Phosphoric Acid SCHEMBL23748616 | 0.95 | ADORA2A (0.69) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL5549330 | 0.89 | ADORA2A (0.73) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL5936728 | 0.89 | ADORA2A (0.73) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL29601760 | 0.89 | ADORA2A (0.73) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL29502687 | 0.89 | ADORA2A (0.66) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL5416581 | 0.88 | ADORA2A (0.76) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL5417952 | 0.88 | ADORA2A (0.76) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL30367149 | 0.88 | ADORA2A (0.79) | ADORA2AADORA3PI4KAPI4K2BPI4K2A | |
| SCHEMBL26130576 | 0.88 | ADORA2A (0.79) | ADORA2AADORA3PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139251-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026102302-A1 | POLYNUCLEOTIDES CONTAINING A MODIFIED 3'-REGION | MODERNATX, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260132406-A1 | RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4731229-A1 | SIRNA, CONJUGATE WHICH CONTAIN SIRNA, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hansoh Bio LLC (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260092276-A1 | Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications | KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) | 2026-04-02 | — | — | US | claimed |
| US-12582668-B2 | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | Arrowhead Pharmaceuticals, Inc. (US) | 2026-03-24 | — | — | US | claimed |
| US-20260078375-A1 | RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3573623-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF FACTOR XII GENE EXPRESSION | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-04 | — | — | EP | claimed |
| US-20260053941-A1 | MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | US | claimed |
| US-20110269820-A1 | SPINAL MUSCULAR ATROPHY TREATMENT VIA TARGETING SMN2 CATALYTIC CORE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2011-11-03 | — | — | US | claimed |
| US-7838657-B2 | compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (intronic splicing silencer), located in the SMN2 gene | UNIVERSITY OF MASSACHUSETTS (US) | 2010-11-23 | — | — | US | claimed |
| US-20100087511-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIVERSITY OF MASSACHUSETTS (US) | 2010-04-08 | — | — | US | claimed |
| US-20080311040-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | FLAGSHIP VENTURES (US) | 2008-12-18 | — | — | US | claimed |
| WO-2008109105-A2 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH SIRNA | FLAGSHIP VENTURES (US) | 2008-09-12 | — | — | WO | claimed |
| US-20070292408-A1 | Spinal Muscular Atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | UNIVERSITY OF MASSACHUSETTS (US) | 2007-12-20 | — | — | US | claimed |
| EP-1556402-A4 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | UNIV MASSACHUSETTS (US) | 2007-10-10 | — | — | EP | claimed |
| EP-1556402-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | University of Massachusetts (US) | 2005-07-27 | — | — | EP | claimed |
| US-20050020521-A1 | Rna interference strands and antibody strands | UNIVERSITY OF MASSACHUSETTS (US) | 2005-01-27 | — | — | US | claimed |
| WO-2004029212-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2004-04-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139251-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | MUC1, CFTR, RBM26 | ADORA2A 1013/4885ADORA3 681/4885PI4KA 4144/4885 |
| US-20110269820-A1 | SPINAL MUSCULAR ATROPHY TREATMENT VIA TARGETING SMN2 CATALYTIC CORE | SMN1; SMN2, MSI2, RBM17 | ADORA2A 3229/4885ADORA3 3605/4885PI4KA 2348/4885 |
| US-12582668-B2 | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | UPF1, RNGTT, SERPINA2 | ADORA2A 658/4885ADORA3 868/4885PI4KA 3677/4885 |
| US-20260132406-A1 | RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use | ACVR1, ACVRL1, METTL16 | ADORA2A 553/4885ADORA3 201/4885PI4KA 273/4885 |
| US-20260053941-A1 | MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | UPF1, MYOF, MBNL1 | ADORA2A 4260/4885ADORA3 4041/4885PI4KA 4592/4885 |
| US-20080311040-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | NSUN3, AGO2, NSUN2 | ADORA2A 2531/4885ADORA3 2007/4885PI4KA 3200/4885 |
| US-20260078375-A1 | RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of Use | METTL16, METTL3, RNMT | ADORA2A 60/4885ADORA3 36/4885PI4KA 520/4885 |
| US-20260092276-A1 | Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications | ASGR1, FCGR2A, LDLR | ADORA2A 131/4885ADORA3 60/4885PI4KA 4678/4885 |
| US-20050020521-A1 | Rna interference strands and antibody strands | AGO2, NSUN3, NSUN2 | ADORA2A 1935/4885ADORA3 1516/4885PI4KA 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.